Plus Therapeutics Stock Analysis
| PSTV Stock | USD 0.73 0.05 7.35% |
Plus Therapeutics is undervalued with Real Value of 4.48 and Target Price of 15.75. The main objective of Plus Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Plus Therapeutics is worth, separate from its market price. There are two main types of Plus Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Plus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Plus Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Plus Stock trading window is adjusted to America/New York timezone.
Plus |
Plus Stock Analysis Notes
The company recorded a loss per share of 2.37. Plus Therapeutics last dividend was issued on the 6th of August 2019. The entity had 1:15 split on the 1st of May 2023. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Plus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Plus Therapeutics contact MD MBA at 737 255 7194 or learn more at https://plustherapeutics.com.Plus Therapeutics Investment Alerts
| Plus Therapeutics generated a negative expected return over the last 90 days | |
| Plus Therapeutics has high historical volatility and very poor performance | |
| Plus Therapeutics has some characteristics of a very speculative penny stock | |
| Plus Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (13.32 M) with loss before overhead, payroll, taxes, and interest of (5.46 M). | |
| Plus Therapeutics currently holds about 20.27 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Plus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Plus Therapeutics Advances Lead Drug Rhenium Obisbemeda for Patients with Leptomeningeal Metastases |
Plus Therapeutics Upcoming and Recent Events
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 18th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Plus Largest EPS Surprises
Earnings surprises can significantly impact Plus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-10-21 | 2021-09-30 | -0.24 | -0.28 | -0.04 | 16 | ||
2023-02-23 | 2022-12-31 | -0.12 | -0.22 | -0.1 | 83 | ||
2023-10-31 | 2023-09-30 | -1.12 | -1.0 | 0.12 | 10 |
Plus Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 | Aigh Capital Management, Llc | 2024-12-31 | 560.9 K | Geode Capital Management, Llc | 2024-12-31 | 58.1 K | Vanguard Group Inc | 2024-12-31 | 32.5 K | Two Sigma Securities, Llc | 2024-12-31 | 14.6 K | Blackrock Inc | 2024-12-31 | 7 K | Tower Research Capital Llc | 2024-12-31 | 4.8 K | Jpmorgan Chase & Co | 2024-09-30 | 200 | Advisor Group Holdings, Inc. | 2024-12-31 | 133 | Sbi Securities Co Ltd | 2024-12-31 | 66.0 |
Plus Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.27 M.Plus Profitablity
The company has Profit Margin (PM) of (2.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.61) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.61.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.40) | (1.47) | |
| Return On Capital Employed | (23.18) | (22.02) | |
| Return On Assets | (1.34) | (1.41) | |
| Return On Equity | 8.89 | 9.34 |
Management Efficiency
Plus Therapeutics has return on total asset (ROA) of (0.9042) % which means that it has lost $0.9042 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.225) %, meaning that it created substantial loss on money invested by shareholders. Plus Therapeutics' management efficiency ratios could be used to measure how well Plus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 9.34 in 2025, whereas Return On Tangible Assets are likely to drop (1.47) in 2025. Total Current Assets is likely to climb to about 17.1 M in 2025, whereas Total Assets are likely to drop slightly above 9.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.49) | (0.47) | |
| Tangible Book Value Per Share | (0.65) | (0.61) | |
| Enterprise Value Over EBITDA | (0.08) | (0.08) | |
| Price Book Value Ratio | (4.69) | (4.45) | |
| Enterprise Value Multiple | (0.08) | (0.08) | |
| Price Fair Value | (4.69) | (4.45) | |
| Enterprise Value | 1.3 M | 1.2 M |
Understanding the operational decisions made by Plus Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 2nd of March, Plus Therapeutics holds the Variance of 28.64, coefficient of variation of (903.12), and Risk Adjusted Performance of (0.07). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Plus Therapeutics, as well as the relationship between them. Please check Plus Therapeutics market risk adjusted performance and treynor ratio to decide if Plus Therapeutics is priced some-what accurately, providing market reflects its current price of 0.73 per share. As Plus Therapeutics is a penny stock we also suggest to check out its jensen alpha numbers.Plus Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Plus Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Plus Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Plus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Plus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Plus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Plus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Plus Therapeutics Outstanding Bonds
Plus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Plus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Plus bonds can be classified according to their maturity, which is the date when Plus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Plus Therapeutics Predictive Daily Indicators
Plus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Plus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Plus Therapeutics Forecast Models
Plus Therapeutics' time-series forecasting models are one of many Plus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Plus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Plus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Plus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Plus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Plus Therapeutics. By using and applying Plus Stock analysis, traders can create a robust methodology for identifying Plus entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (2.44) | (2.56) | |
| Operating Profit Margin | (3.12) | (3.27) | |
| Net Loss | (3.12) | (3.27) | |
| Gross Profit Margin | (1.12) | (1.06) |
Current Plus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Plus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Plus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 15.75 | Strong Buy | 4 | Odds |
Most Plus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Plus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Plus Therapeutics, talking to its executives and customers, or listening to Plus conference calls.
Plus Stock Analysis Indicators
Plus Therapeutics stock analysis indicators help investors evaluate how Plus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Plus Therapeutics shares will generate the highest return on investment. By understating and applying Plus Therapeutics stock analysis, traders can identify Plus Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 18.1 M | |
| Common Stock Shares Outstanding | 3.1 M | |
| Total Stockholder Equity | -1.3 M | |
| Property Plant And Equipment Net | 1.1 M | |
| Cash And Short Term Investments | 8.6 M | |
| Cash | 8.6 M | |
| Accounts Payable | 4.8 M | |
| Net Debt | -4.4 M | |
| 50 Day M A | 1.1516 | |
| Total Current Liabilities | 10.7 M | |
| Other Operating Expenses | 18.2 M | |
| Non Current Assets Total | 1.6 M | |
| Non Currrent Assets Other | 32 K | |
| Stock Based Compensation | 569 K |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.